Royal Bank of Canada’s Aevi Genomic Medicine Inc GNMX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-500
| Closed | – | – | 7305 |
|
|
2019
Q4 | $0 | Buy |
+500
| New | +$68 | ﹤0.01% | 7324 |
|
|
2019
Q1 | – | Sell |
-2,000
| Closed | -$1K | – | 7290 |
|
|
2018
Q4 | $1K | Sell |
2,000
-89
| -4% | -$99 | ﹤0.01% | 6663 |
|
|
2018
Q3 | $2K | Buy |
2,089
+89
| +4% | +$100 | ﹤0.01% | 6560 |
|
|
2018
Q2 | $2K | Hold |
2,000
| – | – | ﹤0.01% | 6309 |
|
|
2018
Q1 | $4K | Sell |
2,000
-25
| -1% | -$47 | ﹤0.01% | 6017 |
|
|
2017
Q4 | $2K | Hold |
2,025
| – | – | ﹤0.01% | 6329 |
|
|
2017
Q3 | $3K | Buy |
2,025
+25
| +1% | +$32 | ﹤0.01% | 6535 |
|
|
2017
Q2 | $3K | Sell |
2,000
-1,165
| -37% | -$1.68K | ﹤0.01% | 6219 |
|
|
2017
Q1 | $6K | Sell |
3,165
-545
| -15% | -$2.47K | ﹤0.01% | 6171 |
|
|
2016
Q4 | $19K | Buy |
3,710
+1,710
| +86% | +$9K | ﹤0.01% | 5810 |
|
|
2016
Q3 | $11K | Hold |
2,000
| – | – | ﹤0.01% | 5762 |
|
|
2016
Q2 | $11K | Hold |
2,000
| – | – | ﹤0.01% | 5731 |
|
|
2016
Q1 | $9K | Sell |
2,000
-41
| -2% | -$169 | ﹤0.01% | 5778 |
|
|
2015
Q4 | $12K | Sell |
2,041
-773
| -27% | -$5.25K | ﹤0.01% | 5919 |
|
|
2015
Q3 | $22K | Buy |
2,814
+1,746
| +163% | +$13.5K | ﹤0.01% | 5538 |
|
|
2015
Q2 | $7K | Buy |
+1,068
| New | +$8.28K | ﹤0.01% | 6188 |
|
Royal Bank of Canada's GNMX Position: Q1 2020 in Review
Royal Bank of Canada sold out of Aevi Genomic Medicine Inc (GNMX) in Q1 2020, closing a stake of 500 shares.
Royal Bank of Canada first reported a position in GNMX in Q2 2015 and held it in 16 quarters. The position peaked at $22K in Q3 2015. 2 funds tracked by Wall St. Rank hold GNMX as of Q1 2020.
- Royal Bank of Canada reported no remaining Aevi Genomic Medicine Inc position as of Q1 2020 after selling out during the quarter.
- Royal Bank of Canada sold 500 Aevi Genomic Medicine Inc shares in Q1 2020.
- Royal Bank of Canada first reported a position in Aevi Genomic Medicine Inc in Q2 2015 and held it in 16 quarters.
- Royal Bank of Canada's Aevi Genomic Medicine Inc position peaked at $22K in Q3 2015.
- 2 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q1 2020.
Based on Royal Bank of Canada's 13F filing for Q1 2020, filed 15 May 2020.